AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38867077 — intervention group
Group type: EXPERIMENTAL
Intervention: PSCA-directed CAR T cells (100 million CAR T cells without lymphodepletion, followed by lymphodepletion)
Number of subjects: 14
Study 38867077 — intervention group
Group type: EXPERIMENTAL
Intervention: PSCA-directed CAR T cells
Number of subjects: 14
Study 38867164 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic therapy protocols
Number of subjects: 134
Study 38867164 — intervention group
Group type: EXPERIMENTAL
Intervention: Broad-spectrum antibiotic therapy ≥ 4 days
Number of subjects: 134
Study 38867164 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescribing ≥ 2 antibiotics
Number of subjects: 134
Study 38867164 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurologic compromise at ICU admission
Number of subjects: 134
Study 38867164 — intervention group
Group type: EXPERIMENTAL
Intervention: Suspected catheter-related bacteraemia
Number of subjects: 134
Study 38867164 — intervention group
Group type: EXPERIMENTAL
Intervention: BI site classified as 'other'
Number of subjects: 134
Study 38867164 — intervention group
Group type: EXPERIMENTAL
Intervention: Sepsis with ≥ 2 organ dysfunctions
Number of subjects: 134
Study 38867164 — intervention group
Group type: EXPERIMENTAL
Intervention: Late-onset ventilator-associated pneumonia
Number of subjects: 134
Study 38867164 — intervention group
Group type: EXPERIMENTAL
Intervention: ≥ 1 risk factor for extended-spectrum β-lactamase-producing Enterobacteriaceae
Number of subjects: 134
Study 38867164 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory failure at ICU admission
Number of subjects: 134
Study 38867164 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspiration pneumonia
Number of subjects: 134
Study 38867192 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic surgery
Number of subjects: 733
Study 38867192 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic aspiration
Number of subjects: 733
Study 38867192 — intervention group
Group type: COMPARATOR
Intervention: Small-bone flap craniotomy
Number of subjects: 733
Study 38867195 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-Isometric Relaxation Technique
Number of subjects: 24
Study 38867195 — intervention group
Group type: COMPARATOR
Intervention: Bowen's Therapy
Number of subjects: 24
Study 38867198 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote patient management (RPM)
Number of subjects: 707
Study 38867198 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 707
Study 38867220 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine (TCM) - primarily herbal medicine (HM)
Number of subjects: 52
Study 38867220 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine (TCM)
Number of subjects: 52
Study 38867235 — intervention group
Group type: EXPERIMENTAL
Intervention: Music intervention
Number of subjects: 0
Study 38867257 — intervention group
Group type: EXPERIMENTAL
Intervention: Tunlametinib 9 mg plus vemurafenib 720 mg, twice daily (BID)
Number of subjects: 72
Study 38867283 — intervention group
Group type: EXPERIMENTAL
Intervention: Experiential Brief Alcohol Intervention (EBAI)
Number of subjects: 810
Study 38867283 — intervention group
Group type: COMPARATOR
Intervention: Facilitation (Control)
Number of subjects: 810
Study 38867283 — intervention group
Group type: EXPERIMENTAL
Intervention: EBAI
Number of subjects: 810
Study 38867292 — intervention group
Group type: EXPERIMENTAL
Intervention: Copeptin
Number of subjects: 519
Study 38867292 — intervention group
Group type: EXPERIMENTAL
Intervention: MRproADM
Number of subjects: 519
Study 38867292 — intervention group
Group type: EXPERIMENTAL
Intervention: MRproANP
Number of subjects: 519
Study 38867292 — intervention group
Group type: EXPERIMENTAL
Intervention: TBI
Number of subjects: 519
Study 38867292 — intervention group
Group type: EXPERIMENTAL
Intervention: aPWV
Number of subjects: 519
Study 38867309 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive Prolonged Exposure (iPE) therapy
Number of subjects: 140
Study 38867309 — intervention group
Group type: COMPARATOR
Intervention: Standard weekly delivered sessions of Prolonged Exposure (PE) therapy
Number of subjects: 140
Study 38867317 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized music therapy (MT) for at least 2 hours per day
Number of subjects: 153
Study 38867317 — intervention group
Group type: EXPERIMENTAL
Intervention: Generalized music therapy (MT) for 12.5 hours per day, subdivided into fifteen 50-min periods
Number of subjects: 153
Study 38867317 — intervention group
Group type: COMPARATOR
Intervention: Control group without music therapy (MT)
Number of subjects: 153
Study 38867317 — intervention group
Group type: EXPERIMENTAL
Intervention: Generalized music therapy (MT)
Number of subjects: 153
Study 38867349 — intervention group
Group type: EXPERIMENTAL
Intervention: Trametinib (oral MEK1/2 inhibitor), administered for a maximum of 12 cycles.
Number of subjects: 10
Study 38867580 — intervention group
Group type: EXPERIMENTAL
Intervention: Mid-urethral sling (MUS) surgery
Number of subjects: 1210
Study 38867580 — intervention group
Group type: COMPARATOR
Intervention: Preoperative condition
Number of subjects: 1210
Study 38867580 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-20 years follow-up after MUS
Number of subjects: 1210
Study 38867580 — intervention group
Group type: COMPARATOR
Intervention: Sexually inactive women
Number of subjects: 1210
Study 38867580 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent pain after MUS
Number of subjects: 1210
Study 38867580 — intervention group
Group type: COMPARATOR
Intervention: Pain as a reason for not being sexually active
Number of subjects: 1210
Study 38867582 — intervention group
Group type: EXPERIMENTAL
Intervention: Azacitidine (5 days treatment prior to chemotherapy)
Number of subjects: 31
Study 38868457 — intervention group
Group type: EXPERIMENTAL
Intervention: Bispectral Index™ (BIS™) monitoring during sedation
Number of subjects: 26
Study 38868457 — intervention group
Group type: COMPARATOR
Intervention: Sedation management at the discretion of the ICU clinical team
Number of subjects: 26
Study 38868491 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma-Focused Cognitive Behavioral Therapy (TF-CBT)
Number of subjects: 19
Study 38868491 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye Movement Desensitization and Reprocessing (EMDR)
Number of subjects: 19
Study 38869019 — intervention group
Group type: COMPARATOR
Intervention: Mirikizumab
Number of subjects: 0
Study 38869034 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term dual antiplatelet therapy (DAPT)
Number of subjects: 1920
Study 38869091 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation
Number of subjects: 1301
Study 38869091 — intervention group
Group type: COMPARATOR
Intervention: Oxygen mask
Number of subjects: 1301
Study 38869518 — intervention group
Group type: EXPERIMENTAL
Intervention: Kidney transplant recipients (KTR)
Number of subjects: 721
Study 38869629 — intervention group
Group type: EXPERIMENTAL
Intervention: Endo-App
Number of subjects: 106
Study 38869632 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary angiography
Number of subjects: 559
Study 38869632 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 559
Study 38869632 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted temperature management
Number of subjects: 559
Study 38869632 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal cardiopulmonary resuscitation (eCPR)
Number of subjects: 559
Study 38869632 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall in-hospital mortality
Number of subjects: 559
Study 38869632 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial rhythm shockable
Number of subjects: 559
Study 38869632 — intervention group
Group type: EXPERIMENTAL
Intervention: Ongoing CPR on hospital admission
Number of subjects: 559
Study 38869632 — intervention group
Group type: EXPERIMENTAL
Intervention: Layperson resuscitation
Number of subjects: 559
Study 38869632 — intervention group
Group type: EXPERIMENTAL
Intervention: Main presumed causes of OHCA
Number of subjects: 559
Study 38869647 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxaliplatin-based chemotherapy
Number of subjects: 405
Study 38869653 — intervention group
Group type: EXPERIMENTAL
Intervention: Disclosure as a stigma management strategy
Number of subjects: 34
Study 38869653 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-disclosure strategies
Number of subjects: 34
Study 38869653 — intervention group
Group type: EXPERIMENTAL
Intervention: Experiences of psychosis stigma
Number of subjects: 34
Study 38869653 — intervention group
Group type: EXPERIMENTAL
Intervention: Understanding from others
Number of subjects: 34
Study 38869683 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital-based training group
Number of subjects: 24
Study 38869683 — intervention group
Group type: COMPARATOR
Intervention: Home-based training group
Number of subjects: 24
Study 38869701 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine infusion at 0.025 µg/kg/min
Number of subjects: 180
Study 38869701 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine infusion at 0.05 µg/kg/min
Number of subjects: 180
Study 38869701 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine infusion at 0.075 µg/kg/min
Number of subjects: 180
Study 38869701 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 180
Study 38869746 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 500 mg orally BID plus celecoxib 200 mg orally once daily for 12 weeks
Number of subjects: 50
Study 38869746 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets BID plus celecoxib 200 mg orally once daily for 12 weeks
Number of subjects: 50
Study 38869771 — intervention group
Group type: EXPERIMENTAL
Intervention: Talazoparib monotherapy
Number of subjects: 61
Study 38869780 — intervention group
Group type: EXPERIMENTAL
Intervention: Newly developed improved radio-TLC method
Number of subjects: 0
Study 38869865 — intervention group
Group type: COMPARATOR
Intervention: Cessation of TKI treatment and follow-up every 3 months.
Number of subjects: 60
Study 38869865 — intervention group
Group type: EXPERIMENTAL
Intervention: Retreatment due to detectable ctDNA and/or elevated CEA levels.
Number of subjects: 60
Study 38869865 — intervention group
Group type: EXPERIMENTAL
Intervention: Retreatment due to progressive disease.
Number of subjects: 60
Study 38869865 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall response rate to TKI retreatment.
Number of subjects: 60
Study 38869865 — intervention group
Group type: EXPERIMENTAL
Intervention: Time to next treatment.
Number of subjects: 60
Study 38869865 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival data.
Number of subjects: 60
Study 38869899 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional Awareness and Expression Therapy (EAET)
Number of subjects: 126
Study 38869899 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 126
Study 38869902 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand scan image group
Number of subjects: 270
Study 38869902 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructional video group
Number of subjects: 270
Study 38869902 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand scan image with instructional video group
Number of subjects: 270
Study 38869902 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 270
Study 38869930 — intervention group
Group type: EXPERIMENTAL
Intervention: PRIOR (Protocol for Increasing Data Integrity in Online Research)
Number of subjects: 1300
Study 38869930 — intervention group
Group type: COMPARATOR
Intervention: Initial protocol for preventing fraudulent participation
Number of subjects: 1300
Study 38869931 — intervention group
Group type: EXPERIMENTAL
Intervention: Liberal transfusion strategy (transfusions initiated at hemoglobin level ≤10 g/dL)
Number of subjects: 742
Study 38869931 — intervention group
Group type: COMPARATOR
Intervention: Restrictive transfusion strategy (transfusions initiated at hemoglobin level ≤7 g/dL)
Number of subjects: 742
Study 38869931 — intervention group
Group type: EXPERIMENTAL
Intervention: Liberal transfusion strategy
Number of subjects: 742
Study 38869931 — intervention group
Group type: COMPARATOR
Intervention: Restrictive transfusion strategy
Number of subjects: 742
Study 38869943 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored eHealth self-management intervention based on the Dutch Medical Dashboard (MD)
Number of subjects: 0
Study 38869943 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally tailored, standardized eHealth self-management intervention
Number of subjects: 0
Study 38869947 — intervention group
Group type: EXPERIMENTAL
Intervention: Selumetinib
Number of subjects: 50
Study 38869978 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressants (specific mention of paroxetine and sertraline)
Number of subjects: 4575
Study 38869978 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 4575
Study 38869978 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 4575
Study 38869978 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4575
Study 38869987 — intervention group
Group type: EXPERIMENTAL
Intervention: Avenciguat 1 mg twice-daily
Number of subjects: 23
Study 38869987 — intervention group
Group type: EXPERIMENTAL
Intervention: Avenciguat 2 mg twice-daily
Number of subjects: 23
Study 38869987 — intervention group
Group type: EXPERIMENTAL
Intervention: Avenciguat 3 mg twice-daily
Number of subjects: 23
Study 38869987 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 38870076 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable monitoring device based on an Internet management platform
Number of subjects: 120
Study 38870076 — intervention group
Group type: COMPARATOR
Intervention: Conventional diabetes treatments
Number of subjects: 120
Study 38870103 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasopressin
Number of subjects: 45
Study 38870103 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II
Number of subjects: 45
Study 38870103 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (Norepinephrine)
Number of subjects: 45
Study 38870156 — intervention group
Group type: EXPERIMENTAL
Intervention: MediYoga
Number of subjects: 46
Study 38870156 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy treatment as usual
Number of subjects: 46
Study 38870517 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Pain Scale (FPS)
Number of subjects: 232
Study 38870573 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported exhaustion (SRE)
Number of subjects: 493
Study 38870573 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-item Physical Frailty Index (4i-PFI)
Number of subjects: 493
Study 38870573 — intervention group
Group type: EXPERIMENTAL
Intervention: Body Mass Index (BMI)
Number of subjects: 493
Study 38870573 — intervention group
Group type: EXPERIMENTAL
Intervention: Timed Up-and-Go (TUG)
Number of subjects: 493
Study 38870573 — intervention group
Group type: EXPERIMENTAL
Intervention: Handgrip Strength (HGS)
Number of subjects: 493
Study 38870745 — intervention group
Group type: EXPERIMENTAL
Intervention: T-VEC plus pembrolizumab in cohort 1
Number of subjects: 72
Study 38870745 — intervention group
Group type: EXPERIMENTAL
Intervention: T-VEC plus pembrolizumab in cohort 2
Number of subjects: 72
Study 38870745 — intervention group
Group type: EXPERIMENTAL
Intervention: T-VEC plus pembrolizumab in cohort 3
Number of subjects: 72
Study 38870745 — intervention group
Group type: EXPERIMENTAL
Intervention: T-VEC plus pembrolizumab in cohort 4
Number of subjects: 72
Study 38870745 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment-related adverse events (TRAEs)
Number of subjects: 72
Study 38870749 — intervention group
Group type: EXPERIMENTAL
Intervention: Qilong capsule (QLC) combined with conventional treatment (CT)
Number of subjects: 2302
Study 38870749 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (CT) alone
Number of subjects: 2302
Study 38870931 — intervention group
Group type: EXPERIMENTAL
Intervention: Serplulimab (300 mg) plus HLX04 (7.5 mg/kg) and XELOX
Number of subjects: 114
Study 38870931 — intervention group
Group type: COMPARATOR
Intervention: Placebo (300 mg) plus bevacizumab (7.5 mg/kg) and XELOX
Number of subjects: 114
Study 38870977 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanoliposomal irinotecan (70 mg/m²) plus fluorouracil plus leucovorin
Number of subjects: 100
Study 38870977 — intervention group
Group type: COMPARATOR
Intervention: Fluorouracil plus leucovorin
Number of subjects: 100
Study 38870979 — intervention group
Group type: EXPERIMENTAL
Intervention: Garsorasib (D-1553), open-label, single-arm, phase 2 trial
Number of subjects: 123
Study 38870979 — intervention group
Group type: EXPERIMENTAL
Intervention: Garsorasib (D-1553)
Number of subjects: 123
Study 38871018 — intervention group
Group type: EXPERIMENTAL
Intervention: Binge drinkers (BDs)
Number of subjects: 82
Study 38871018 — intervention group
Group type: COMPARATOR
Intervention: Non/low-drinkers (N/LDS)
Number of subjects: 82
Study 38871148 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation (FMT)
Number of subjects: 467
Study 38871148 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated FMT treatments
Number of subjects: 467
Study 38871269 — intervention group
Group type: EXPERIMENTAL
Intervention: AAV5-hRKp.RPGR
Number of subjects: 0
Study 38871269 — intervention group
Group type: COMPARATOR
Intervention: Deferred group (control)
Number of subjects: 0
Study 38871445 — intervention group
Group type: EXPERIMENTAL
Intervention: IQOS 3.0
Number of subjects: 90
Study 38871454 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based STI screening for youth
Number of subjects: 5601
Study 38871487 — intervention group
Group type: EXPERIMENTAL
Intervention: CG-806
Number of subjects: 0
Study 38871558 — intervention group
Group type: EXPERIMENTAL
Intervention: Talquetamab (bispecific antibody targeting GPRC5D)
Number of subjects: 0
Study 38871558 — intervention group
Group type: EXPERIMENTAL
Intervention: Talquetamab
Number of subjects: 0
Study 38871565 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care ultrasound (POCUS) integrated with clinical score and d-dimer testing
Number of subjects: 1979
Study 38871565 — intervention group
Group type: EXPERIMENTAL
Intervention: Age-adjusted d-dimer
Number of subjects: 1979
Study 38871657 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus 0.02 mg/kg intravenous infusion over 4 hours prior to organ retrieval
Number of subjects: 414
Study 38871657 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 414
Study 38871679 — intervention group
Group type: COMPARATOR
Intervention: 10% metronidazole
Number of subjects: 192
Study 38871679 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% metronidazole + 2% diltiazem
Number of subjects: 192
Study 38871679 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% metronidazole + 4% lidocaine
Number of subjects: 192
Study 38871679 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% metronidazole + 2% diltiazem + 4% lidocaine
Number of subjects: 192
Study 38871679 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 192
Study 38871702 — intervention group
Group type: EXPERIMENTAL
Intervention: Error-corrected-NGS-MRD
Number of subjects: 189
Study 38871702 — intervention group
Group type: EXPERIMENTAL
Intervention: WT1-MRD
Number of subjects: 189
Study 38871702 — intervention group
Group type: EXPERIMENTAL
Intervention: NPM1 mutation detection
Number of subjects: 189
Study 38871702 — intervention group
Group type: EXPERIMENTAL
Intervention: NGS-MRD
Number of subjects: 189
Study 38871705 — intervention group
Group type: EXPERIMENTAL
Intervention: palbociclib, fulvestrant, trastuzumab, and pyrotinib
Number of subjects: 15
Study 38871715 — intervention group
Group type: EXPERIMENTAL
Intervention: Community gardening intervention
Number of subjects: 291
Study 38871878 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance-based reimbursement model (PBRM)
Number of subjects: 0
Study 38871878 — intervention group
Group type: COMPARATOR
Intervention: Fixed-rate model (FRM)
Number of subjects: 0
Study 38871878 — intervention group
Group type: COMPARATOR
Intervention: Up-front allocation model (UFAM)
Number of subjects: 0
Study 38871947 — intervention group
Group type: EXPERIMENTAL
Intervention: DAPT > 12 months
Number of subjects: 1000
Study 38871947 — intervention group
Group type: COMPARATOR
Intervention: DAPT ≤ 12 months
Number of subjects: 1000
Study 38871947 — intervention group
Group type: EXPERIMENTAL
Intervention: DAPT > 12 months (HIR)
Number of subjects: 1000
Study 38871947 — intervention group
Group type: EXPERIMENTAL
Intervention: DAPT > 12 months (Technical HIR)
Number of subjects: 1000
Study 38871975 — intervention group
Group type: EXPERIMENTAL
Intervention: Botensilimab (BOT) plus balstilimab (BAL)
Number of subjects: 148
Study 38872109 — intervention group
Group type: EXPERIMENTAL
Intervention: BCI-FES paired with PT
Number of subjects: 66
Study 38872109 — intervention group
Group type: COMPARATOR
Intervention: Dose-matched PT sessions
Number of subjects: 66
Study 38872174 — intervention group
Group type: EXPERIMENTAL
Intervention: Transrectal biopsy (TRUS)
Number of subjects: 0
Study 38872174 — intervention group
Group type: COMPARATOR
Intervention: Local anaesthetic transperineal biopsy (LATP)
Number of subjects: 0
Study 38872173 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILI) with low carbohydrate, high protein calorie-restricted diet (CRD), exercise, and intensive counseling from a dietitian
Number of subjects: 226
Study 38872173 — intervention group
Group type: COMPARATOR
Intervention: Control group with balanced calorie-restricted diet (CRD), exercise, and standard counseling
Number of subjects: 226
Study 38872173 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILI)
Number of subjects: 226
Study 38872173 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 226
Study 38872193 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet + Supplementation: individualized diet supplemented with 604 mg of omega-3 fatty acids, three times a day
Number of subjects: 91
Study 38872193 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet + Placebo: individualized diet + 1 g of soybean oil
Number of subjects: 91
Study 38872193 — intervention group
Group type: COMPARATOR
Intervention: Placebo: 1 g of soybean oil daily, no dietetic intervention
Number of subjects: 91